Quanta Inc (fka QNTA)

[falon]

Dapper10,

You as the rest of us have reasons to be concern however when looking at the facts we have a very reasonable opportunity to create a paradigm shift in the pharmaceutical arena. It has not and will not be easy.

Let's look at the facts:

1. This is a penny stock which is a very risky investment.

2. The share structure make it less risky.
https://www.otcmarkets.com/stock/QNTA/security

3. QNTA has a Pre-IND application moving through the FDA protocols.

Subsequent to the acknowledgement of the trial, the FDA has requested that the Company complete two additional toxicology studies in animals. Since adoption of COVID-19 vaccinations, the FDA altered its protocol for measuring toxicology to include studying it at the DNA level. As this is a newer development, the agency has asked Medolife to provide data in this regard. Medolife has the product and protocol necessary to complete these studies in short-order.

“Given the ever-changing landscape of COVID-19, we are pleased that the FDA recognizes that our original proposed study was a proof-of-concept design under our original Pre-IND submission,” said Christina DiArcangelo, CEO and Founder of Affinity Bio Partners, a contracted clinical consultant for Medolife.

DiArcangelo has 24 years of experience in the global biotechnology, pharmaceutical, device, and nutraceutical industries and has worked on products that have received FDA approval on 25 pharmaceutical drugs.


4. All hands on deck due to Covid-19

While some available treatments have been helpful there is nothing on the market that after contracting Covid, getting very ill and being hospitalized will shut the virus down.

Is Escozine the answer?

BURBANK, CA / ACCESSWIRE / January 27, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA) today announced In a recent study, a total of 400 patients in the Dominican Republic - where, a majority tested positive for COVID-19, and a small portion were COVID-19 symptomatic even though they tested negative for COVID-19 - reported a 100 percent improvement in symptoms after being administered Escozine®. Many of the patients participating in the study reported severe COVID-19 symptoms, such as difficulty breathing, pain and high fever, which Escozine® was able to relieve within 5 days of treatment. Even patients under ventilators were discharged within days, thanks to this novel product. Located in Santo Domingo, Dominican Republic, The Cruz Jiminian Clinic has carried out this ongoing study since August 2020, and has reported 0 COVID-19 related deaths after the clinic began administering Escozine®. Escozine®, produced by Medolife Rx, Inc., ("Medolife"), is a therapeutic consisting of small molecule peptides derived from a specific species of scorpions, Rhopalurus princeps, endemic to the Dominican Republic. After the successful study, Escozine® is on fast-track to be registered with the Ministry of Health in the Dominican Republic in Q1 2021. Medolife also submitted the study data to the US FDA, which is currently under review for permission to repeat the clinical trial in the United States. In addition to supporting the recovery of COVID-19 patients, Escozine® was registered and certified for cancer treatment by the Ministry of Health in the Dominican Republic in 2010.

5. Although not profitable, the company is generating revenue and have products that should increase the revenues moving forward. They did have problems with their supply chain as most companies had due to Covid-19.

6. Follow the science:

Patent

The basic principle described in the US Patent # US 8097284 B2 leads to molecular excitement of vibration produced by an electromagnetic field generator, leading to absorption of the quanta of energy for higher potency of the blue scorpion extract, which increases its effectiveness on overall human health at a deep cellular level. Specific frequencies, as well as harmonics, are used to achieve a resonance effect between the generated electromagnetic frequencies and the molecular frequency of the small molecular peptide, specific amino-acids and 59 essential minerals contained in the blue scorpion extract; the electromagnetic vibrational frequency acts as an energy donor and components contained in the scorpion extract act as an energy acceptor. This energy transfer gives more strength, force and potency to the Blue Scorpion extract.

7. THE small MOLECULE:


Why Small Molecules Are Still a Big Deal

Small molecules continue to play a role in innovative treatments for the four major indications that account for more than half of global pharma growth: oncology, diabetes, autoimmune, and respiratory diseases. For example, small molecule protein kinase inhibitors, of which the FDA has approved 48, are becoming more important in cancer therapy. Another area of growth entails the use of small and large molecules in combination; antibody drug conjugates (ADC), which couple potent small molecule payloads with the targeting capabilities of monoclonal antibodies, allowing for more precise treatment of cancer (and fewer side effects than standard chemotherapy).

Small companies are driving innovation. The vast majority of small molecule drugs in development are held by small or “emerging” companies with fewer than 100 employees. Our analysis suggests that these companies account for approximately 4,400 candidate compounds – or 70 percent of the small-molecule pipeline. These companies are increasingly bringing successful compounds to commercial production, and typically require access to enabling technologies, development, and manufacturing partners to do so.

8. The thought of Scorpion Venom being a solution to different medical maladies is uncommon, unbelievable, exceptional, unique, unknown, unprecedented, unusual, new, novel, normal and obscure or anyway one may want to describe the situation.

The fact that science supports their research and the FDA has and IND application pending suggests something GREAT is on the horizon.



In closing QNTA is on a lot of peoples radar especially "Big Pharma".

Once QNTA succeed with the IND for Covid-19 treatments then it opens the door for other treatments such as cancer.

The available studies show promising results in both areas.

FACTS not fiction

Timely, Interesting, Accurate......

Also once QNTA gets the IND for Covid-19 we may get some calls from Big Pharma about some patrnerships.

Other FACTS:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165456032

https://themedicinemaker.com/manufacture/why-small-molecules-are-still-a-big-deal

https://ir.quantrx.com/news-events/press-releases?year=2021&category=all